Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 288

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 288
---
ations)
under the Series C Certificate of Designations or Series C Warrants.

Reservation Requirements.
So long as any Series C Preferred Stock remains outstanding, we shall at all times reserve at least 250% of the number of shares
of Common Stock as shall from time to time be necessary to effect the conversion of all Series C Preferred Stock then outstanding.

Common Stock

Voting

Each holder of Common Stock
is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors, with
the exception of certain matters relating solely to the terms of one or more outstanding series of preferred stock. Under the Charter,
our stockholders do not have cumulative voting rights. Because of this, the holders of a majority of the shares of Common Stock entitled
to vote in any election of directors can elect all of the directors standing for election.

Dividends

Subject to preferences that
may apply to any then-outstanding Preferred Stock, the holders of Common Stock are entitled to receive ratably those dividends, if any,
as may be declared from time to time by the Board out of legally available funds.

Liquidation

In the event of our liquidation,
dissolution or winding up, holders of Common Stock will be entitled to share ratably in the net assets legally available for distribution
to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted
to the holders of any then-outstanding shares of Preferred Stock.

<div align='center'>169</div>

Preemptive or Similar Rights

Holders of Common Stock
have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the Common
Stock. The rights, preferences and privileges of the holders of Common Stock are subject to, and may be adversely affected by, the rights
of the holders of shares of any series of Preferred Stock that we may designate in the future.

Warrants

The outstanding warrants
consist of (i) Public Warrants, (ii) Private Placement Warrants, (iii) warrants initially issued by CERo Therapeutics, Inc. and converted
into warrants to purchase Common Stock in connection with our initial business combination (the “Conversion Warrants”), (iv)
the Series A Warrants, (v) the Series C Warrants and (vi) the Preferred Warrants.

Public Warrants

General. Each Public
Warrant entitles the registered holder to purchase one share of Common